Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 12 g - injection, solution - excipient ingredients: maltose - intragam p is indicated for replacement igg therapy in: * primary immunodeficiency; * myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; * congenital or acquired immune deficiency syndrome with recurrent infections. intragam p is indicated for immunomodulatory therapy in: * idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; * allogeneic bone marrow transplantation; * kawasaki disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 3 g - injection, solution - excipient ingredients: maltose - intragam p is indicated for replacement igg therapy in: * primary immunodeficiency; * myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; * congenital or acquired immune deficiency syndrome with recurrent infections. intragam p is indicated for immunomodulatory therapy in: * idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; * allogeneic bone marrow transplantation; * kawasaki disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: maltose - intragam p is indicated for replacement igg therapy in: * primary immunodeficiency; * myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; * congenital or acquired immune deficiency syndrome with recurrent infections. intragam p is indicated for immunomodulatory therapy in: * idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; * allogeneic bone marrow transplantation; * kawasaki disease; * guillain-barre syndrome (gbs).

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: maltose - intragam p is indicated for replacement igg therapy in: - primary immunodeficiency; - myeloma and chronic lymphocytic leukaemia with severe secondary - hypogammaglobulinaemia and recurrent infections; - congenital or acquired immune deficiency syndrome with recurrent infections. intragam p is indicated for immunomodulatory therapy in: - idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; - allogeneic bone marrow transplantation; - kawasaki disease; - guillain-barr? syndrome (gbs).

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 mg/ml - injection, solution - excipient ingredients: maltose - intragam p is indicated in replacement igg therapy in: . primary immunodeficiency; . myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; . congenital acquired immune deficiency syndrome with recurrent infections. intragam is also indicated for immunoomodulatory therapy in idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; allogenic bone marrow transplantation; kawasaki disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - tetanus immunoglobulin, quantity: 4000 iu; human immunoglobulin g, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: maltose; water for injections; human immunoglobulin a - tetanus immunoglobulin-vf (for intravenous use) is used in the management of clinical tetanus.

Australia - English - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 40 g - liquid, multipurpose - excipient ingredients: glycine; water for injections - gamunex normal immunoglobulin (human), 10% is a replacement therapy in: - primary imunodeficiency (pi) diseases. - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation in: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barre syndrome (gbs). - chronic inflammatory demyelinating polyneuropathy (cidp),-kawasaki disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - equine antithymocyte immunoglobulin, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; glycine; hydrochloric acid - indications as at 11 april 2002 : atgam is indicated for renal transplant patients in whom reduction of peripheral t-lympocyte function as measured by rosette-forming cell assay could be desirable. during controlled clinical trials, this immunosuppression has been demonstrated in renal allograft recipients treated with atgam. when it was administered prophylactically with conventional immunosuppressive therapy, atgam delayed the onset of the first rejection episode, and when it was administered at the time of the first rejection, atgam resolved the acute rejection episode more frequently than did conventional therapy alone.

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - human immunoglobulin g, quantity: 100 mg/ml - injection - excipient ingredients: octoxinol 10; maltose; tributyl phosphate; water for injections; human immunoglobulin a - replacement therapy in: primary immunodeficiency syndromes: congenital agammaglobulinaemia and hypogammaglobulinaemia; common variable immunodeficiency; severe combined immunodeficiencies; wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. children with congenital acquired immune deficiency syndrome (aids) who have repeated bacterial infections; immunomodulation: idiopathic thrombocytopenic purpura, in adults or children with a high risk of bleeding or prior to surgery to correct platelet count. guillain barre syndrome. kawasaki disease. allogeneic bone marrow transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - human immunoglobulin g, quantity: 100 mg/ml - injection - excipient ingredients: maltose; octoxinol 10; tributyl phosphate; water for injections; human immunoglobulin a - replacement therapy in: primary immunodeficiency syndromes: congenital agammaglobulinaemia and hypogammaglobulinaemia; common variable immunodeficiency; severe combined immunodeficiencies; wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. children with congenital acquired immune deficiency syndrome (aids) who have repeated bacterial infections; immunomodulation: idiopathic thrombocytopenic purpura, in adults or children with a high risk of bleeding or prior to surgery to correct platelet count. guillain barre syndrome. kawasaki disease. allogeneic bone marrow transplantation.